Drug intelligence / Profile preview

AGM-130

Development stage: Unknown
Lead developer: Rockwell International
Modality: Peptides
Administration: Intravenous

Overview

AGM-130 is a peptide-based Cyclin-dependent kinase (CDK) inhibitor developed by Anygen, currently in Phase 1 clinical development for the treatment of Triple Negative Breast Cancer (TNBC). As a peptide therapeutic, AGM-130 is designed to target and inhibit the activity of CDKs, which are essential regulators of the cell cycle that are frequently dysregulated in aggressive cancers like TNBC. By blocking these kinases, the drug aims to induce cell cycle arrest and inhibit the proliferation of malignant cells. This modality represents a shift from traditional small-molecule CDK inhibitors, potentially offering different binding characteristics or specificity profiles within the CDK family.

Targets

GSK3 (Glycogen synthase kinase 3 beta)AHR (Aryl hydrocarbon receptor)AURK (Aurora kinase family)CDK (CDK family)

Beyond the preview

Go deeper on AGM-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGM-130.

Explore the full profile